Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Johnston WT, Lightfoot TJ, Simpson J, Roman E. Childhood cancer survival: a report from the United Kingdom Childhood Cancer Study. Cancer Epidemiol. 34(6), 659–666 (2010).
  MedlineGoogle Scholar
• 2 Tasian SK, Hunger SP. Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics. Br. J. Haematol. 176(6), 867–882 (2017).
  Medline CASGoogle Scholar
• 3 Pui C-H, Yang JJ, Hunger SP et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J. Clin. Oncol. 33(27), JCO.2014.59.1636 (2015).
  Google Scholar
• 4 Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 381(9881), 1943–1955 (2013).
  MedlineGoogle Scholar
• 5 Mei L, Ontiveros EP, Griffiths EA, Thompson JE, Wang ES, Wetzler M. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev. 29(4), 243–249 (2015).
  Medline CASGoogle Scholar
• 6 Lopez-Lopez E, Gutierrez-Camino A, Bilbao-Aldaiturriaga N, Pombar-Gomez M, Martin-Guerrero I, Garcia-Orad A. Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics 15(10), 1383–1398 (2014).
  CASGoogle Scholar
• 7 Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin. Chem. 42(8 Pt 2), 1322–1329 (1996).
  Medline CASGoogle Scholar
• 8 Salazar J, Altes A, del Rio E et al. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics J. 12(5), 379–385 (2012).
  Medline CASGoogle Scholar
• 9 Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med. 338(8), 499–505 (1998).
  Medline CASGoogle Scholar
• 10 Shomron N. microRNAs and pharmacogenomics. Pharmacogenomics 11(5), 629–632 (2010).
  CASGoogle Scholar
• 11 Rukov JL, Shomron N. microRNA pharmacogenomics: post-transcriptional regulation of drug response. Trends Mol. Med. 17(8), 412–423 (2011). • An approach to understanding the miRNA role in drug efficacy and toxicity.
  Medline CASGoogle Scholar
• 12 Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 91(23), 2001–2008 (1999).
  Medline CASGoogle Scholar
• 13 Fernandez CA, Smith C, Yang W et al. HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood 124(8), 1266–1276 (2014).
  Medline CASGoogle Scholar
• 14 Moriyama T, Relling MV, Yang JJ. Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood. 125(26), 3988–3995 (2015).
  Medline CASGoogle Scholar
• 15 Maxwell RR, Cole PD. Pharmacogenetic predictors of treatment-related toxicity among children with acute lymphoblastic leukemia. Curr. Hematol. Malig. Rep. 12(3), 176–186 (2017).
  MedlineGoogle Scholar
• 16 Trevino LR, Shimasaki N, Yang W et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol. 27(35), 5972–5978 (2009).
  Medline CASGoogle Scholar
• 17 Diouf B, Crews KR, Lew G et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313(8), 815–823 (2015).
  Medline CASGoogle Scholar
• 18 Yang JJ, Landier W, Yang W et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J. Clin. Oncol. 33(11), 1235–1242 (2015).
  Medline CASGoogle Scholar
• 19 Liu Y, Fernandez CA, Relling MV. Response to ‘PNPLA3 rs738409 and hepatotoxicity in children with B-cell acute lymphoblastic leukemia: a validation study in a Spanish cohort’. Clin. Pharmacol. Ther. 102(6), 907 (2017).
  Medline CASGoogle Scholar
• 20 Ramsey LB, Panetta JC, Smith C et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 121(6), 898–904 (2013).
  Medline CASGoogle Scholar
• 21 Tanaka Y, Kato M, Hasegawa D et al. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br. J. Haematol. 171(1), 109–115 (2015).
  Medline CASGoogle Scholar
• 22 Gutierrez-Camino A, Martin-Guerrero I, Garcia-Orad A. PNPLA3 rs738409 and hepatotoxicity in children with B-cell acute lymphoblastic leukemia: a validation study in a Spanish cohort. Clin. Pharmacol. Ther. 102(6), 906 (2017).
  Medline CASGoogle Scholar
• 23 Lopez-Lopez E, Martin-Guerrero I, Ballesteros J et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer. 57(4), 612–619 (2011).
  MedlineGoogle Scholar
• 24 Li J, Wang X-R, Zhai X-W et al. Association of SLCO1B1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia. Int. J. Clin. Exp. Med. 8(4), 6109–6113 (2015).
  Medline CASGoogle Scholar
• 25 Liang D-C, Yang C-P, Liu H-C et al. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J. 16(6), 536–539 (2016).
  Medline CASGoogle Scholar
• 26 Ivanov M, Barragan I, Ingelman-Sundberg M. Epigenetic mechanisms of importance for drug treatment. Trends Pharmacol. Sci. 35(8), 384–396 (2014). •• Review on epigenetic modifications in drug treatment success and egidrug concept.
  Medline CASGoogle Scholar
• 27 Majchrzak-Celińska A, Baer-Dubowska W. Pharmacoepigenetics: an element of personalized therapy? Expert Opin. Drug Metab. Toxicol. 13(4), 387–398 (2017).
  Medline CASGoogle Scholar
• 28 Lopomo A, Coppedè F. Pharmacoepigenetics and pharmacoepigenomics of gastrointestinal cancers. Expert Rev. Gastroenterol. Hepatol. 12(1), 1–14 (2017).
  MedlineGoogle Scholar
• 29 Ballestar E, Esteller M. Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger. Biochem. Cell Biol. 83(3), 374–384 (2005).
  Medline CASGoogle Scholar
• 30 Dejeux E, Rønneberg JA, Solvang H et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol. Cancer 9(1), 68 (2010).
  MedlineGoogle Scholar
• 31 Iorio MV, Piovan C, Croce CM. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim. Biophys. Acta 1799(10–12), 694–701 (2010).
  Medline CASGoogle Scholar
• 32 Kitange GJ, Mladek AC, Carlson BL et al. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin. Cancer Res. 18(15), 4070–4079 (2012).
  Medline CASGoogle Scholar
• 33 Saeidimehr S, Ebrahimi A, Saki N, Goodarzi P, Rahim F. microRNA-based linkage between aging and cancer: from epigenetics view point. Cell J. 18(2), 117–126.
  MedlineGoogle Scholar
• 34 Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer 10(6), 389–402 (2010).
  Medline CASGoogle Scholar
• 35 Sana J, Faltejskova P, Svoboda M, Slaby O. Novel classes of non-coding RNAs and cancer. J. Transl. Med. 10(1), 103 (2012).
  Medline CASGoogle Scholar
• 36 Rukov JL, Wilentzik R, Jaffe I, Vinther J, Shomron N. Pharmaco-miR: linking microRNAs and drug effects. Brief. Bioinform. 15(4), 648–659 (2014).
  Medline CASGoogle Scholar
• 37 Li Y, Zhu X, Gu J et al. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci. 101(4), 948–954 (2010).
  Medline CASGoogle Scholar
• 38 Xia L, Zhang D, Du R et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 123(2), 372–379 (2008).
  Medline CASGoogle Scholar
• 39 Lopez-Lopez E, Gutierrez-Camino A, Pinan MA et al. Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia. PLoS ONE 9(3), e91261 (2014). • Study that finds the association between mir-1206 and mucositis.
  MedlineGoogle Scholar
• 40 Schotte D, de Menezes RX, Moqadam FA et al. microRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 96(5), 703–711 (2011). • Study that reveals the upregulation of miR-125b, miR-99a and miR-100 in vincristine and daunorubicin-resistant patients.
  MedlineGoogle Scholar
• 41 Avigad S, Verly IRN, Lebel A et al. miR expression profiling at diagnosis predicts relapse in pediatric precursor B-cell acute lymphoblastic leukemia. Genes. Chromosomes Cancer 55(4), 328–339 (2016).
  Medline CASGoogle Scholar
• 42 Han BW, Feng DD, Li ZG et al. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum. Mol. Genet. 20(24), 4903–4915 (2011).
  Medline CASGoogle Scholar
• 43 Nemes K, Csóka M, Nagy N et al. Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia. Pathol. Oncol. Res. 21(3), 597–604 (2015).
  Medline CASGoogle Scholar
• 44 Mei Y, Gao C, Wang K et al. Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci. 105(4), 463–472 (2014).
  Medline CASGoogle Scholar
• 45 Cao L, Wang N, Pan J et al. Clinical significance of microRNA-34b expression in pediatric acute leukemia. Mol. Med. Rep. 13(3), 2777–2784 (2016).
  Medline CASGoogle Scholar
• 46 Chen P, Shen T, Wang H, Ke Z, Liang Y. microRNA-185-5p restores glucocorticoid sensitivity by suppressing the mammalian target of rapamycin complex (mTORC) signaling pathway to enhance glucocorticoid receptor autoregulation. Leuk. Lymphoma 58(11), 2657–2667 (2017).
  CASGoogle Scholar
• 47 Liang YN, Tang YL, Ke ZY et al. miR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor. J. Steroid Biochem. Mol. Biol. 162, 62–68 (2016).
  Google Scholar
• 48 Labib HA, Elantonuy NG, Ibrahim NF, Alnagar AA. Upregulation of microRNA-21 is a poor prognostic marker in patients with childhood B cell acute lymphoblastic leukemia. Hematology 22(7), 392–397 (2017).
  Medline CASGoogle Scholar
• 49 Akbari Moqadam F, Lange-Turenhout EAM, Ariës IM, Pieters R, den Boer ML. miR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia. Leuk. Res. 37(10), 1315–1321 (2013). • Study that points out to the relation of miR-125b, miR-99a and miR-100 coexpression with vincristine resistance.
  Medline CASGoogle Scholar
• 50 Schotte D, Lange-Turenhout EAM, Stumpel DJPM et al. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica 95(10), 1675–1682 (2010).
  Medline CASGoogle Scholar
• 51 Piatopoulou D, Avgeris M, Marmarinos A et al. miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment. Br. J. Cancer 117(6), 801–812 (2017).
  Medline CASGoogle Scholar
• 52 Kandi R, Gutti U, Saladi RGV, Gutti RK. miR-125b and miR-99a encoded on chromosome 21 co-regulate vincristine resistance in childhood acute megakaryoblastic leukemia. Hematol. Oncol. Stem Cell Ther. 8(2), 95–97 (2015).
  Medline CASGoogle Scholar
• 53 Vergani E, Di Guardo L, Dugo M et al. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget 7(4), 4428–4441 (2016).
  MedlineGoogle Scholar
• 54 Kubota D, Kosaka N, Fujiwara T et al. miR-125b and miR-100 are predictive biomarkers of response to induction chemotherapy in osteosarcoma. Sarcoma 2016, 1390571 (2016).
  MedlineGoogle Scholar
• 55 Lu Y, Zhao X, Liu Q et al. lncRNA miR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat. Med. 23(11), 1331–1341 (2017).
  Medline CASGoogle Scholar
• 56 Kim E-A, Kim S-W, Nam J et al. Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs. Oncotarget 7(22), 31832–31846 (2016).
  MedlineGoogle Scholar
• 57 Qin X, Sun L, Wang J. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway. Cell Biol. Int. 41(10), 1110–1118 (2017).
  Medline CASGoogle Scholar
• 58 Wang Y, Li Z, He C et al. microRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells. Mol. Dis. 44(3), 191–197 (2010).
  Medline CASGoogle Scholar
• 59 Akbari Moqadam F, Lange-Turenhout EAM, van der Veer A et al. microRNA signature in BCR-ABL1-like and BCR-ABL1-positive childhood acute lymphoblastic leukemia: similarities and dissimilarities. Leuk. Lymphoma 55(8), 1942–1945 (2014).
  MedlineGoogle Scholar
• 60 Schotte D, Akbari Moqadam F, Lange-Turenhout EAM et al. Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia. Leukemia 25(9), 1389–1399 (2011).
  Medline CASGoogle Scholar
• 61 de Oliveira JC, Scrideli CA, Brassesco MS et al. Differential miRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological features. Leuk. Res. 36(3), 293–298 (2012).
  MedlineGoogle Scholar
• 62 Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42(Database issue), D68–D73 (2014).
  Medline CASGoogle Scholar
• 63 Lopez-Lopez E, Gutierrez-Camino A, Astigarraga I et al. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. Pharmacogenomics 17(7), 731–741 (2016).
  CASGoogle Scholar
• 64 Iparraguirre L, Gutierrez-Camino A, Umerez M et al. miR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia. Pharmacogenet. Genomics 26(11), 517–525 (2016).
  Medline CASGoogle Scholar
• 65 Gutierrez-Camino A, Oosterom N, den Hoed MAH et al. The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenet. Genomics 27, 303–306 (2017). • Study that replicates the association of miR-1206 and mucositis in a different cohort.
  Medline CASGoogle Scholar
• 66 Wang S, Sun L, Zeng W, Wu W, Zhang G. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia. Med. Oncol. 31(7), 62 (2014).
  MedlineGoogle Scholar
• 67 Wang S-M, Zeng W-X, Wu W-S, Sun L-L, Yan D. Association between MTHFR microRNA binding site polymorphisms and methotrexate concentrations in Chinese pediatric patients with acute lymphoblastic leukemia. J. Gene Med. 19(11), e2990 (2017).
  Google Scholar
• 68 den Hoed MAH, Lopez-Lopez E, te Winkel ML et al. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenomics J. 15(3), 248–254 (2015).
  Medline CASGoogle Scholar
• 69 Umerez M, Gutierrez-Camino Á, Muñoz-Maldonado C, Martin-Guerrero I, Garcia-Orad A. MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy. Pharmgenomics Pers. Med. 10, 69–78 (2017).
  Medline CASGoogle Scholar
• 70 Hou Z, Matherly LH. Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr. Top. Membr. 73, 175–204 (2014).
  Medline CASGoogle Scholar
• 71 Dzikiewicz-Krawczyk A. microRNA polymorphisms as markers of risk, prognosis and treatment response in hematological malignancies. Crit. Rev. Oncol. Hematol. 93(1), 1–17 (2015).
  MedlineGoogle Scholar
• 72 Preskill C, Weidhaas JB. SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers. Crit. Rev. Oncog. 18(4), 327–340 (2013).
  MedlineGoogle Scholar
• 73 Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GSA, Banerjee D, Bertino JR. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl. Acad. Sci. USA 104(33), 13513–13518 (2007).
  Medline CASGoogle Scholar
• 74 Barger JF, Nana-Sinkam SP. microRNA as tools and therapeutics in lung cancer. Respir. Med. 109(7), 803–812 (2015).
  MedlineGoogle Scholar
• 75 Bouchie A. First microRNA mimic enters clinic. Nat. Biotechnol. 31(7), 577 (2013).
  Medline CASGoogle Scholar
• 76 Beg MS, Brenner AJ, Sachdev J et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest. New Drugs 35(2), 180–188 (2017).
  Medline CASGoogle Scholar
• 77 Ling H, Girnita L, Buda O, Calin GA. Non-coding RNAs: the cancer genome dark matter that matters! Clin. Chem. Lab. Med. 55(5), 705–714 (2017).
  Medline CASGoogle Scholar
• 78 Kao SC, Fulham M, Wong K et al. A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 191(12), 1467–1469 (2015).
  MedlineGoogle Scholar
• 79 Malek E, Jagannathan S, Driscoll JJ. Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget 5(18), 8027–8038 (2014). • Role of long-noncoding RNAs, in drug response, other epigenetic mechanism that offer a promising field to avoid drug resistance.
  MedlineGoogle Scholar
• 80 Tani H, Torimura M. Development of cytotoxicity-sensitive human cells using overexpression of long non-coding RNAs. J. Biosci. Bioeng. 119(5), 604–608 (2015).
  Medline CASGoogle Scholar
• 81 Liu Y, Xu N, Liu B et al. Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines. Oncotarget 7(28), 43835–43851 (2016).
  MedlineGoogle Scholar
• 82 Gong WJ, Peng JB, Yin JY et al. Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer. Acta Pharmacol. Sin. 38(4), 581–590 (2017).
  Medline CASGoogle Scholar
• 83 Qiao L, Liu X, Tang Y, Zhao Z, Zhang J, Liu H. Knockdown of long non-coding RNA prostate cancer-associated ncRNA transcript 1 inhibits multidrug resistance and c-Myc-dependent aggressiveness in colorectal cancer Caco-2 and HT-29 cells. Mol. Cell. Biochem. doi:10.1007/s11010-017-3177-8 (2017) (Epub ahead of print).
  Google Scholar
• 84 Li P, Zhang X, Wang H et al. MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Mol. Cancer Ther. 16(4), 739–751 (2017).
  Medline CASGoogle Scholar
• 85 Ouimet M, Drouin S, Lajoie M et al. A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration. Oncotarget 8(5), 7477–7488 (2017).
  MedlineGoogle Scholar
• 86 Yan H, Zhang D-Y, Li X et al. Long non-coding RNA GAS5 polymorphism predicts a poor prognosis of acute myeloid leukemia in Chinese patients via affecting hematopoietic reconstitution. Leuk. Lymphoma 58(8), 1948–1957 (2017).
  Medline CASGoogle Scholar
• 87 Ingelman-Sundberg M, Gomez A. The past, present and future of pharmacoepigenomics. Pharmacogenomics 11(5), 625–627 (2010).
  CASGoogle Scholar
• 88 PubMed. www.ncbi.nlm.nih.gov/pubmed
  Google Scholar